MX369412B - Peptidos. - Google Patents

Peptidos.

Info

Publication number
MX369412B
MX369412B MX2016001744A MX2016001744A MX369412B MX 369412 B MX369412 B MX 369412B MX 2016001744 A MX2016001744 A MX 2016001744A MX 2016001744 A MX2016001744 A MX 2016001744A MX 369412 B MX369412 B MX 369412B
Authority
MX
Mexico
Prior art keywords
peptide
peptides
present
tshr
graves
Prior art date
Application number
MX2016001744A
Other languages
English (en)
Other versions
MX2016001744A (es
Inventor
David Wraith
Original Assignee
Apitope Int Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Int Nv filed Critical Apitope Int Nv
Publication of MX2016001744A publication Critical patent/MX2016001744A/es
Publication of MX369412B publication Critical patent/MX369412B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido por lo menos parcialmente derivable del Receptor de la Hormona Estimulante de la Tiroides (TSHR), cuyo péptido tiene la capacidad de enlazarse a una molécula MHC in vitro y ser presentado a un linfocito T sin procesamiento de antígeno adicional; la presente invención también se refiere al uso de dichos péptidos para la prevención o supresión de la activación de la formación de autoanticuerpos en la Enfermedad de Graves.
MX2016001744A 2013-08-06 2014-08-06 Peptidos. MX369412B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201314052A GB201314052D0 (en) 2013-08-06 2013-08-06 Peptides
PCT/IB2014/063739 WO2015019302A2 (en) 2013-08-06 2014-08-06 Peptides

Publications (2)

Publication Number Publication Date
MX2016001744A MX2016001744A (es) 2016-05-18
MX369412B true MX369412B (es) 2019-11-07

Family

ID=49224229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001744A MX369412B (es) 2013-08-06 2014-08-06 Peptidos.

Country Status (32)

Country Link
US (2) US9938329B2 (es)
EP (1) EP3030259B1 (es)
JP (1) JP6476181B2 (es)
KR (1) KR102431507B1 (es)
CN (1) CN105636980B (es)
AU (1) AU2014304108B2 (es)
BR (1) BR112016002572A2 (es)
CA (1) CA2920321C (es)
CY (1) CY1120212T1 (es)
DK (1) DK3030259T3 (es)
ES (1) ES2664045T3 (es)
GB (1) GB201314052D0 (es)
HK (1) HK1219058A1 (es)
HR (1) HRP20180452T1 (es)
HU (1) HUE038569T2 (es)
IL (1) IL243892B (es)
LT (1) LT3030259T (es)
MX (1) MX369412B (es)
MY (1) MY177371A (es)
NO (1) NO3030259T3 (es)
NZ (1) NZ717350A (es)
PE (1) PE20160778A1 (es)
PH (1) PH12016500218A1 (es)
PL (1) PL3030259T3 (es)
PT (1) PT3030259T (es)
RS (1) RS57196B1 (es)
RU (1) RU2676149C2 (es)
SG (1) SG11201600895SA (es)
SI (1) SI3030259T1 (es)
UA (1) UA120746C2 (es)
WO (1) WO2015019302A2 (es)
ZA (1) ZA201600729B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
CN107249617A (zh) * 2014-12-24 2017-10-13 艾匹托普国际股份有限公司 组合物
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
EP3369743A1 (en) 2017-03-01 2018-09-05 advanceCOR GmbH Cyclic peptides for the treatment of graves' disease
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927461T2 (de) 1989-12-14 1997-03-20 B.R.A.H.M.S Diagnostica Gmbh, 12099 Berlin Polypeptide mit Thyrotropinrezeptor-Aktivität, kodierende Nukleinsäuresequenzen für solche Rezeptoren und Verwendung dieser Polypeptide
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
FR2842812A1 (fr) 2002-07-26 2004-01-30 Pf Medicament Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
JP2006188507A (ja) * 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
JP2009517015A (ja) * 2005-11-21 2009-04-30 ドクトル フェニング ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 組換えポリペプチドならびにtshレセプターに対する自己抗体を検出及び/又は定量化する方法
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides

Also Published As

Publication number Publication date
LT3030259T (lt) 2018-05-10
MY177371A (en) 2020-09-14
JP6476181B2 (ja) 2019-02-27
MX2016001744A (es) 2016-05-18
KR102431507B1 (ko) 2022-08-10
EP3030259B1 (en) 2017-12-27
EP3030259A2 (en) 2016-06-15
US9938329B2 (en) 2018-04-10
GB201314052D0 (en) 2013-09-18
SG11201600895SA (en) 2016-03-30
PT3030259T (pt) 2018-03-20
RS57196B1 (sr) 2018-07-31
WO2015019302A3 (en) 2015-08-27
BR112016002572A2 (pt) 2017-09-12
RU2676149C2 (ru) 2018-12-26
ZA201600729B (en) 2019-12-18
HUE038569T2 (hu) 2018-10-29
CN105636980B (zh) 2021-05-04
ES2664045T3 (es) 2018-04-18
AU2014304108A1 (en) 2016-02-25
PH12016500218A1 (en) 2016-04-25
PL3030259T3 (pl) 2018-07-31
CN105636980A (zh) 2016-06-01
US20180327463A1 (en) 2018-11-15
CY1120212T1 (el) 2018-12-12
HRP20180452T1 (hr) 2018-06-01
AU2014304108B2 (en) 2018-03-08
JP2016527304A (ja) 2016-09-08
UA120746C2 (uk) 2020-02-10
HK1219058A1 (en) 2017-03-24
PE20160778A1 (es) 2016-08-06
US20160185833A1 (en) 2016-06-30
CA2920321A1 (en) 2015-02-12
IL243892B (en) 2019-11-28
SI3030259T1 (en) 2018-07-31
IL243892A0 (en) 2016-04-21
NZ717350A (en) 2019-03-29
RU2016107873A (ru) 2017-09-12
CA2920321C (en) 2022-10-18
NO3030259T3 (es) 2018-05-26
WO2015019302A2 (en) 2015-02-12
KR20160036059A (ko) 2016-04-01
DK3030259T3 (en) 2018-04-16
US10730919B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
PH12016500218A1 (en) Peptides
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
ZA202200648B (en) Immunoglobulins and uses thereof
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EA201690494A1 (ru) Ацилированные аналоги глюкагона
MX339083B (es) Proteinas de enlace a cd127.
JO3576B1 (ar) أجسام مضادة لـ tau واستخداماتها
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MY185593A (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
EP2403871A4 (en) SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN
NZ594198A (en) Neil3 peptides and vaccines including the same
EA201070681A1 (ru) Пептиды fviii и их применение для индукции толерантности у больных гемофилией
MX344791B (es) Antígeno sustituto en enfermedades autoinmunes.
MX2017008505A (es) Composicion.
PH12015501033A1 (en) Peptides
MY166516A (en) Tomm34 peptides and vaccines including the same
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2015009086A (es) Peptido.

Legal Events

Date Code Title Description
FG Grant or registration